Reframing Obesity Webinar 3: Managing Concerns and Improving Adherence (April 22, 2025)-Slides

Slides

Pdf Summary

The document is a module titled "Optimizing Care: Managing Concerns and Improving Adherence," authored by Jennifer N. Clements, PharmD, at the University of South Carolina College of Pharmacy. It addresses the management of anti-obesity medications, focusing on concerns such as side effects, muscle mass loss, and access barriers, and provides a comprehensive approach to addressing these concerns.<br /><br />The document covers various cases, including a 36-year-old woman initiating a GLP-1 receptor agonist for weight management who expresses concerns about side effects. The suggested approach is to educate the patient about the medication's side effects to build trust and improve treatment adherence. <br /><br />A second case discusses managing side effects post-dose escalation of semaglutide in a 47-year-old woman, recommending reducing the dose as a strategy to manage gastrointestinal symptoms while maintaining efficacy.<br /><br />In another scenario, a 60-year-old man worries about muscle mass loss from medication. It is advised to increase protein intake and resistance training to preserve muscle mass during weight loss.<br /><br />The document also deals with a 35-year-old woman who finds it challenging to afford her anti-obesity medication. It suggests submitting a prior authorization request to secure insurance coverage.<br /><br />Throughout, the module emphasizes the importance of patient education and provider-patient communication to improve adherence and safety. Additionally, the document includes evidence-based strategies for mitigating various adverse effects associated with GLP-1 receptor agonists, such as nausea, thyroid cancer risk, and gallbladder disease. The use of the 5As framework (Ask, Assess, Advise, Agree, Assist) and a comprehensive care model, addressing nutrition, activity, behavioral modification, and pharmacotherapy, are also highlighted as pillars of successful weight management.

Keywords

anti-obesity medications

GLP-1 receptor agonist

side effects management

treatment adherence

patient education

muscle mass preservation

prior authorization

5As framework

comprehensive care model

pharmacotherapy